Form 8-K · Current report
Procter & Gamble 8-K, filed Oct 22, 2026
- Filed
- CIK
- 0000080424
- Accession no.
- 0000080424-26-000252
Summary
Procter & Gamble reported first-quarter fiscal 2027 organic sales growth of 4.0% and core earnings per share of $2.00, up 1%, and maintained its full-year organic sales growth guidance of +1% to +3% while updating net sales growth guidance to +2% to +4%. The company cited a challenging macroeconomic environment and expected rising cost headwinds in coming quarters.
Key points
- Organic volume rose 2.4%, mix added 1.1% and pricing added 0.4%; all six regions and 10 of 10 product categories grew organic sales.
- Core EPS was $2.00, up 1% versus the prior year, and $1.99 on a currency-neutral basis, flat versus the prior year.
- FY2027 core EPS growth guidance was maintained at +0% to +3%, with all-in EPS growth of +1% to +5%.
- Guidance excludes potential headwinds including significant commodity cost increases, tariff changes and supply chain disruption.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 7.01Regulation FD Disclosure
- 9.01Financial Statements and Exhibits
From the filing
Item 7.01 - Regulation FD Disclosure On October 22, 2026, The Procter & Gamble Company (the "Company") issued a press release announcing its first quarter results and hosted a conference call related to those results. The Company is furnishing on Form 8-K a series of slides referenced in the conference call, which are also posted on the Company's website. This 8-K is being furnished pursuant to Item 7.01, "Regulation FD Disclosure." Item 9.01 - Financial Statements and Exhibits (d): The following exhibits are being filed herewith: Exhibit No. Description 99.1 Informational Slides Provided by The Procter & Gamble Company dated October 22, 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.